CN1668290B - 用于抑制血小板凝集的修饰氨基酸 - Google Patents

用于抑制血小板凝集的修饰氨基酸 Download PDF

Info

Publication number
CN1668290B
CN1668290B CN038169231A CN03816923A CN1668290B CN 1668290 B CN1668290 B CN 1668290B CN 038169231 A CN038169231 A CN 038169231A CN 03816923 A CN03816923 A CN 03816923A CN 1668290 B CN1668290 B CN 1668290B
Authority
CN
China
Prior art keywords
platelet aggregation
modified amino
calcitonin
amino acid
cnac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN038169231A
Other languages
English (en)
Chinese (zh)
Other versions
CN1668290A (zh
Inventor
S·D·贝特曼
M·阿兹里亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1668290A publication Critical patent/CN1668290A/zh
Application granted granted Critical
Publication of CN1668290B publication Critical patent/CN1668290B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN038169231A 2002-07-17 2003-07-16 用于抑制血小板凝集的修饰氨基酸 Expired - Fee Related CN1668290B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39689802P 2002-07-17 2002-07-17
US60/396,898 2002-07-17
PCT/EP2003/007739 WO2004006907A1 (en) 2002-07-17 2003-07-16 Modified amino acid for the inhibition of platelet aggregation

Publications (2)

Publication Number Publication Date
CN1668290A CN1668290A (zh) 2005-09-14
CN1668290B true CN1668290B (zh) 2010-04-28

Family

ID=30116066

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038169231A Expired - Fee Related CN1668290B (zh) 2002-07-17 2003-07-16 用于抑制血小板凝集的修饰氨基酸

Country Status (12)

Country Link
US (3) US20060106110A1 (enExample)
EP (1) EP1556027B1 (enExample)
JP (1) JP4541884B2 (enExample)
CN (1) CN1668290B (enExample)
AT (1) ATE538782T1 (enExample)
AU (1) AU2003257473A1 (enExample)
BR (1) BR0312712A (enExample)
CA (1) CA2492378C (enExample)
ES (1) ES2379949T3 (enExample)
PT (1) PT1556027E (enExample)
TW (1) TW200403052A (enExample)
WO (1) WO2004006907A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007521232A (ja) 2003-08-08 2007-08-02 アブジェニックス・インコーポレーテッド 副甲状腺ホルモン（ｐｔｈ）に対する抗体およびその使用
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
EP1907571B1 (en) 2005-06-15 2017-04-26 Complete Genomics Inc. Nucleic acid analysis by random mixtures of non-overlapping fragments
CN101627011A (zh) * 2005-09-19 2010-01-13 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
US8895777B2 (en) 2006-08-31 2014-11-25 Emisphere Technologies Inc Compounds and compositions for delivering active agents
PL2059260T3 (pl) * 2006-08-31 2014-03-31 Novartis Ag Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20110207693A1 (en) * 2010-02-24 2011-08-25 Emisphere Technologies, Inc. Oral B12 Therapy
RU2504536C1 (ru) * 2012-08-20 2014-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Производное амида салициловой кислоты, обладающее антибактериальной, противогрибковой и антилизоцимной активностью

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1190893A (zh) * 1995-03-31 1998-08-19 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
WO2000059863A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
WO2002045754A2 (en) * 2000-12-06 2002-06-13 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260321A (en) * 1984-11-12 1993-11-09 Sandoz Ltd. Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins
US5733647A (en) * 1992-11-05 1998-03-31 Polymer Innovations, Inc. Insole
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP0993831B1 (en) * 1997-02-07 2008-01-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
CN1190893A (zh) * 1995-03-31 1998-08-19 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2000059863A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
WO2002045754A2 (en) * 2000-12-06 2002-06-13 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEONE-BAY A ET AL."ORAL DELIVERY OF BIOLOGICALLYACTIVEPARATHYROID HORMONE".PHARMACEUTICAL RESEARCH18 7.2001,18(7),964-970.
LEONE-BAY A ET AL."ORAL DELIVERY OF BIOLOGICALLYACTIVEPARATHYROID HORMONE".PHARMACEUTICAL RESEARCH18 7.2001,18(7),964-970. *

Also Published As

Publication number Publication date
JP4541884B2 (ja) 2010-09-08
AU2003257473A1 (en) 2004-02-02
ES2379949T3 (es) 2012-05-07
TW200403052A (en) 2004-03-01
BR0312712A (pt) 2005-04-26
JP2005535670A (ja) 2005-11-24
WO2004006907A1 (en) 2004-01-22
CA2492378A1 (en) 2004-01-22
US20120088833A1 (en) 2012-04-12
US8664211B2 (en) 2014-03-04
US20060106110A1 (en) 2006-05-18
CA2492378C (en) 2011-06-14
EP1556027A1 (en) 2005-07-27
CN1668290A (zh) 2005-09-14
PT1556027E (pt) 2012-04-10
EP1556027B1 (en) 2011-12-28
US20080280817A1 (en) 2008-11-13
ATE538782T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
US8664211B2 (en) Modified amino acid for the inhibition of platelet aggregation
RU2287999C2 (ru) Фармацевтические композиции для перорального введения фармакологически действующих веществ
AU2002234547A1 (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents
JP6118107B2 (ja) Ｒａの処置のためのカルシトニンの使用
CN1809377B (zh) 包含微粉化形式的传送剂的口服给药药物组合物
US12404300B2 (en) Mitochondria-targeting peptides
BRPI0312712B1 (pt) Use of a pharmaceutical composition comprising an inhibitory amount of platelet aggregation of the modified 5-CNAC amino acid
HK1059565B (en) Pharmaceutical compositions for the oral delivery of calcitonin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100428

Termination date: 20180716

CF01 Termination of patent right due to non-payment of annual fee